Post-marketing safety concerns of sotorasib: A disproportionality analysis based on FDA adverse event reporting system

Background: Sotorasib has been approved for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Due to the limitations of clinical trials, potential adverse events (AEs) and long-term safety issues cannot be detected. The presente...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yiling Ding, Hongyan Su, Yamin Shu, Jing Chen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2024-05-01
coleção:	Heliyon
Assuntos:	Sotorasib FAERS AEs Disproportionality analyses WSP
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2405844024064685
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!